Viewing Study NCT01164267


Ignite Creation Date: 2025-12-25 @ 12:28 AM
Ignite Modification Date: 2026-01-31 @ 4:16 AM
Study NCT ID: NCT01164267
Status: COMPLETED
Last Update Posted: 2013-11-25
First Post: 2010-07-15
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Marginal Zone B-cell Lymphoma View
Keywords: